EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting KIT prevents brain arteriovenous malformations driven by ALK1-deficient angiogenic endothelial cells

Elise Drapé, Lauranne Carrier, Gael Cagnone, Atik Rohmana Maftuhatul Fuad, Mathilde Bizou, Damian Sanchez, Typhaine Anquetil, Jack Wang, Halima Drissi Touzani Walali, Adnan Gopinadhan, Patrick Piet van Vliet, Joel P Howard und 5 weitere

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci197587 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Elise Drapé und 16 weiteren Autor:innen. Beteiligte Einrichtung: Département De Pharmacologie Et De Physiologie, Faculté de médecine, Université de Montréal, Montréal, Centre De Recherche CHU St. Justine, Montréal,…. Hauptthemen laut MEDLINE: Endothelial Cells, Intracranial Arteriovenous Malformations, Activin Receptors, Type II, Proto-Oncogene Proteins c-kit. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hereditary hemorrhagic telangiectasia type 2 (HHT2), caused by mutations in ACVRL1 (also known as ALK1 ), is characterized by brain arteriovenous malformations (bAVMs), abnormal artery–vein connections for which treatment options remain limited. Despite evidence of endothelial cell (EC) heterogeneity, its role in bAVM pathogenesis remains poorly defined. Using EC-specific inducible Alk1 -knockout mice ( Alk1iECKO ) and regionally resolved single-cell RNA sequencing, we showed that loss of ALK1 signaling induces bAVMs predominantly in the perineural vascular plexus. This process is driven by the emergence of a KIT + angiogenic EC population with human AVM-like transcriptional features, including tip cell markers and activation of PI3K and KRAS signaling pathways. Cross-species analyses and validation in human samples demonstrated that KIT expression is conserved in ECs from both sporadic and HHT2 bAVMs. Drug-repurposing analysis identified KIT as a top actionable target, and we showed that Kit is directly repressed by BMP9/ALK1/SMAD4 signaling. Pharmacological inhibition of KIT reduced angiogenic reprogramming and vascular malformations in vivo without affecting normal vasculature. These findings identify a pathogenic angiogenic EC state and position KIT signaling as a therapeutically actionable pathway in bAVMs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endothelial CellsIntracranial Arteriovenous MalformationsActivin Receptors, Type IIProto-Oncogene Proteins c-kitTelangiectasia, Hereditary HemorrhagicAngiogenesisAnimalsHumansMiceMice, KnockoutSmad4 ProteinSignal TransductionActivin Receptors, Type IGrowth Differentiation Factor 2Neovascularization, Pathologic

Stichwörter der Autor:innen

AngiogenesisCell biologyEndothelial cellsTranscriptomicsVascular biology

Substanzen

Acvrl1 protein, mouseActivin Receptors, Type IIProto-Oncogene Proteins c-kitACVRL1 protein, humanSmad4 ProteinActivin Receptors, Type IGrowth Differentiation Factor 2Smad4 protein, mouse

Autor:innen und Institutionen

  • Département De Pharmacologie Et De Physiologie, Faculté de médecine, Université de Montréal, Montréal, Centre De Recherche CHU St. Justine, Montréal, Quebec, Canada.
  • Centre De Recherche CHU St. Justine, Montréal, Quebec, Canada.
  • Département De Biochimie, Faculté de médecine, Université de Montréal, Centre De Recherche CHU St. Justine, Montréal, Quebec, Canada.
  • Department of Anatomy and Cell Biology, School of Biomedical Sciences, McGill University, Montréal, Quebec, Canada.
  • Département De Pathologie Et Biologie Cellulaire, Faculté de médecine, Université de Montréal, Centre De Recherche CHU St. Justine, Montréal, Quebec, Canada.
  • Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Förderung

  • Canadian Institutes of Health Research

Zitieren

APA

Drapé, E., Carrier, L., Cagnone, G., Fuad, A. R. M., Bizou, M., Sanchez, D., Anquetil, T., Wang, J., Touzani Walali, H. D., Gopinadhan, A., van Vliet, P. P., Howard, J. P., Ibnat, M., Andelfinger, G., Winkler, E., Larrivée, B., & Dubrac, A. (2026). Targeting KIT prevents brain arteriovenous malformations driven by ALK1-deficient angiogenic endothelial cells. Journal of Clinical Investigation. https://doi.org/10.1172/jci197587

Vancouver

Drapé E, Carrier L, Cagnone G, Fuad ARM, Bizou M, Sanchez D, et al. Targeting KIT prevents brain arteriovenous malformations driven by ALK1-deficient angiogenic endothelial cells. Journal of Clinical Investigation. 2026. doi:10.1172/jci197587

BibTeX
@article{Drap2026,
  author = {Drapé, Elise and Carrier, Lauranne and Cagnone, Gael and Fuad, Atik Rohmana Maftuhatul and Bizou, Mathilde and Sanchez, Damian and Anquetil, Typhaine and Wang, Jack and Touzani Walali, Halima Drissi and Gopinadhan, Adnan and van Vliet, Patrick Piet and Howard, Joel P and Ibnat, Mysha and Andelfinger, Gregor and Winkler, Ethan and Larrivée, Bruno and Dubrac, Alexandre},
  title = {Targeting KIT prevents brain arteriovenous malformations driven by ALK1-deficient angiogenic endothelial cells},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci197587}
}
Kostenlos starten →